Trodelvy has a chance to score in a study designed to expand its use, but given Gilead’s R&D track record nothing is certain.
Cstone/EQRX and Shanghai Junshi/Coherus might have approvable anti-PD-(L)1 projects, but can Keytruda be challenged on price?
The first of 2021’s eight remaining oncology meetings kicks off next week. Here’s what to look out for.
The Junshi/Coherus drug only beat chemotherapy, and its study was run not in the US but in China.
Retifanlimab gets knocked back by a US adcom. Could a rival now beat it to become the eighth anti-PD-(L)1 to reach the US market?
The long overdue advent of US cut-price oncology drugs is a major theme at this year’s Asco, and Junshi’s toripalimab leads the way.
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
Datopotamab, a project with a very similar mechanism to Trodelvy, shows impressive early data in triple-negative breast cancer.